UK markets open in 2 hours 50 minutes

Repligen Corporation (RGEN)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
157.06-3.92 (-2.44%)
At close: 04:00PM EDT
157.06 0.00 (0.00%)
After hours: 04:41PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close160.98
Open154.59
Bid156.97 x 100
Ask157.17 x 100
Day's range152.19 - 159.35
52-week range110.45 - 211.13
Volume759,238
Avg. volume527,851
Market cap8.77B
Beta (5Y monthly)1.01
PE ratio (TTM)212.24
EPS (TTM)0.74
Earnings date01 May 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est204.62
  • GlobeNewswire

    Repligen to Report First Quarter 2024 Financial Results

    Webcast and Conference Call to Be Held Wednesday, May 1, 2024, at 8:30 a.m. ETWALTHAM, Mass., April 17, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its first quarter 2024 financial results on Wednesday, May 1, 2024. The Company will issue a press release before the market opens and will host a conference call at 8:30 a.m. ET to discuss business updates and financial results for the three- month reporting period ended March 31, 2024. Th

  • Insider Monkey

    Artisan Mid Cap Fund Trimmed Repligen Corporation (RGEN) after Share Appreciation

    Artisan Partners, an investment management company, released its “Artisan Mid Cap Fund” first quarter 2024 investor letter. A copy of the same can be downloaded here. In the first quarter, the fund’s Investor Class fund ARTMX returned 10.41%, Advisor Class fund APDMX posted a return of 10.40%, and Institutional Class fund APHMX returned 10.44%, compared […]

  • GlobeNewswire

    Repligen Appoints Maggie A. Pax to Board of Directors

    WALTHAM, Mass., March 19, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced the appointment to its Board of Directors of life sciences industry executive Maggie A. Pax. This appointment expands the size of Repligen’s board from eight to nine members. Ms. Pax brings to Repligen over 25 years of experience leading the development and execution of growth strategies for global companies. This includes eight years with Thermo Fisher Scientific, where, from 2016–2020, she ser